Merck
  • Home
  • Search Results
  • Long-term results of cornea collagen cross-linking with riboflavin for keratoconus.

Long-term results of cornea collagen cross-linking with riboflavin for keratoconus.

Indian journal of ophthalmology (2013-08-09)
Vinay Agrawal
ABSTRACT

Corneal collagen cross-linking with riboflavin and UVA light (CXL) is the only method designed to arrest the progression of keratoconus. Visual improvement generally starts 3 months after treatment. Reduction is coma seen on aberrometry in early postoperative phase is also responsible for the improvement in visual acuity. In the light of currently available data we can thus say that CXL is a safe procedure that is successful in arresting keratoconus.

MATERIALS
Product Number
Brand
Product Description

Riboflavin for peak identification, European Pharmacopoeia (EP) Reference Standard
Supelco
Riboflavin (B2), analytical standard
Sigma-Aldrich
(−)-Riboflavin, from Eremothecium ashbyii, ≥98%
Supelco
Riboflavin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
(−)-Riboflavin, meets USP testing specifications
Sigma-Aldrich
(−)-Riboflavin, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥98%
Riboflavin, European Pharmacopoeia (EP) Reference Standard
USP
Riboflavin, United States Pharmacopeia (USP) Reference Standard